Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865779 | 0.89 | LMNA (0.58) | LMNAHTTHDAC1MAPTSIRT2 | |
| SCHEMBL2522600 | 0.83 | LMNA (0.53) | LMNAHTTHDAC1MAPTSIRT2 | |
| SCHEMBL2264435 | 0.81 | ALDH1A1 (0.61) | LMNAHTTHDAC1MAPTSMN1; SMN2 | |
| SCHEMBL13762029 | 0.81 | HDAC1 (0.67) | LMNAHTTHDAC1MAPTSMN1; SMN2 | |
| SCHEMBL25753418 | 0.81 | LMNA (0.51) | LMNAHTTHDAC1MAPTSIRT2 | |
| SCHEMBL162828 | 0.81 | TSHR (0.54) | LMNAHTTMAPTSIRT2CYP2C9 | |
| SCHEMBL3716265 | 0.81 | SRD5A2 (0.53) | LMNAHTTCYP2C9SMN1; SMN2EPHX1 | |
| SCHEMBL13701770 | 0.81 | HDAC2 (0.59) | LMNAHTTMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL3037706 | 0.80 | HDAC1 (0.60) | LMNAHTTHDAC1JAK2 | |
| SCHEMBL21016381 | 0.79 | EPHX2 (0.51) | LMNAHTTMAPTSIRT2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875007-B1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8987314-B2 | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-13 | — | — | US | disclosed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LIPE, CEL | LMNA 1733/4885HTT 3880/4885HDAC1 188/4885 |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | PTGER2, PTGES2, PTGS2 | LMNA 3384/4885HTT 4623/4885HDAC1 1267/4885 |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | CYP19A1, CYP4B1, CYP3A4 | LMNA 629/4885HTT 4588/4885HDAC1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.